A5011217027- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- HIV, Drug Use, Sexual Risk
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Viral-associated cancers and disorders
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Healthcare Systems and Practices
- Tuberculosis Research and Epidemiology
- Pharmacological Effects and Toxicity Studies
- Immune Cell Function and Interaction
- Syphilis Diagnosis and Treatment
- Sex work and related issues
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lymphoma Diagnosis and Treatment
- Lipoproteins and Cardiovascular Health
- Reproductive tract infections research
- SARS-CoV-2 and COVID-19 Research
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Medication Adherence and Compliance
- Cytomegalovirus and herpesvirus research
University Hospital of Lausanne
2016-2025
University of Lausanne
2016-2025
Swiss HIV Cohort Study
2009-2025
University of Zurich
2011-2024
University Hospital of Bern
2009-2024
University of Geneva
2017-2024
University Hospital of Zurich
2005-2024
University of Basel
2006-2024
Institute of Social and Preventive Medicine
2015-2024
University of Bern
2011-2024
BackgroundHealth care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are utmost importance to patients, clinicians, health-care planners. We examined changes 3 year survival patients starting combination antiretroviral therapy (ART) between 1996 2013.MethodsWe analysed data from 18 European North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible this analysis...
To determine the prevalence of cognitive complaints and HIV-associated neurocognitive disorders (HANDs) in a cohort aviremic HIV-positive patients. evaluate relevance HIV dementia scale to detect HANDs.Assessment HANDs with neuropsychological tests.Two hundred HIV-infected patients undetectable HIV-1 RNA concentrations plasma, no history major opportunistic infection central nervous system past 3 years, current use intravenous drugs, depression answered questionnaire designed elicit...
Background. Patterns of morbidity and mortality among human immunodeficiency virus (HIV)–infected individuals taking antiretroviral therapy are changing as a result immune reconstitution improved survival. We studied the influence aging on epidemiology non-AIDS diseases in Swiss HIV Cohort Study.
Background Mortality among HIV ‐infected persons is decreasing, and causes of death are changing. Classification deaths hampered because low autopsy rates, frequent outside hospitals, shortcomings I nternational S tatistical C lassification D iseases R elated H ealth P roblems ( ICD ‐10) coding. Methods We studied mortality wiss ohort tudy SHCS ) participants (1988–2010) using the oding auses eath in CoDe protocol (2005–2009). Furthermore, we linked data to N ational SNC cause registry....
The advent of highly active antiretroviral therapy (HAART) in 1996 led to a decrease the incidence Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but not other cancers, among people with HIV or AIDS (PWHA). It also marked increases their life expectancy.We conducted record-linkage study between Swiss Cohort Study nine cantonal cancer registries. In total, 9429 PWHA provided 20,615, 17,690, 15,410 person-years pre-, early-, late-HAART periods, respectively. Standardised ratios vs...
Background: Cardiovascular disease and non-AIDS malignancies have become major causes of death among HIV-infected individuals. The relative impact lifestyle HIV-related factors are debated. Methods: We estimated associations smoking with mortality more than 1 year after antiretroviral therapy (ART) initiation individuals enrolled in European North American cohorts. IDUs were excluded. Causes assigned using standardized procedures. used abridged life tables to estimate expectancies....
To estimate life expectancy over 25 years in HIV-positive people and to compare their with recent estimates for the general population, by education.Patients aged 20 or older enrolled Swiss HIV Cohort Study 1988-2013 were eligible. Patients alive 2001 matched up 100 residents, sex, year of birth, education. Life at age was estimated monotherapy (1988-1991), dual therapy (1992-1995), early combination antiretroviral (cART, 1996-1998), later cART (1999-2005) (2006-2013) eras. Parametric...
Abstract Background Advancements in access to antiretroviral therapy (ART) and human immunodeficiency virus (HIV) care have led a decline AIDS-related deaths among people with HIV (PWH) Switzerland. However, data on the ongoing changes causes of death PWH over past 15 years are scarce. Methods We investigated all reported Swiss Cohort Study between 2005 2022. Causes were categorized using Coding Death protocol. The statistical analysis included demographic stratification identify time trends...
The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)-infected individuals receiving potent antiretroviral therapy (ART) shows high variability. We studied the determinants and clinical relevance of incomplete restoration.Longitudinal was analyzed 293 participants Swiss HIV Cohort Study who had a plasma HIV-1 RNA load <1000 copies/mL for > or =5 years. stratified by 5 years after initiation ART (> =500 cells/microL defined as complete response, <500 an response)....
To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics, we performed extensive genotyping 15 relevant single nucleotide polymorphism in 169 study participants, and full resequencing individuals abnormal EFV plasma levels. Seventy-seven (45.5%) carried a known (CYP2B6★6,★11,★15, or ★18) new loss/diminished-function alleles. Resequencing defined two loss-of-function alleles: allele ★27 (marked by 593T>C [M198T]), that results 85% decrease enzyme activity...
Human immunodeficiency virus (HIV)-infected persons may be at increased risk for developing type 2 diabetes mellitus because of viral coinfection and adverse effects treatment.We studied associations new-onset with hepatitis B C coinfections antiretroviral therapy in participants the Swiss HIV Cohort Study, using Poisson regression.A total 123 6513 experienced during 27,798 person-years follow-up (PYFU), resulting an incidence 4.4 cases per 1000 PYFU (95% confidence interval [CI], 3.7-5.3...
Background: Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have comprehensively compared their safety profiles. Methods: Forty-eight-week data presented from this multicenter, randomized, open-label study comparing the profiles of abacavir/lamivudine tenofovir/emtricitabine, both administered with efavirenz, in HLA-B*5701-negative HIV-1-infected adults. Results: Three hundred eighty-five subjects...
Early virological failure of antiretroviral therapy associated with the selection drug-resistant human immunodeficiency virus type 1 in treatment-naive patients is very critical, because significantly increases risk subsequent failures. Therefore, we evaluated possible role minority quasispecies 1, which are undetectable at baseline by population sequencing, regard to early failure.We studied 4 who experienced a first-line regimen lamivudine, tenofovir, and either efavirenz or nevirapine 18...
Background Potential drug–drug interactions (PDDIs) might expand with new combination antiretroviral therapies (ART) and polypharmacy related to increasing age comorbidities. We investigated the prevalence of comedications PDDIs within a large HIV cohort, their effect on ART efficacy tolerability. Methods All medications were prospectively recorded in 1,497 ART-treated patients screened for using customized version Liverpool drug database. Results Overall, 68% (1,013/1,497) had comedication...
Background: Adherence is one of the most crucial issues in clinical management HIV-infected patients receiving antiretroviral therapy (ART). Methods: A 2-item adherence questionnaire was introduced into Swiss HIV Cohort Study July 2003. All 3607 eligible were on ART for ≥6 months and their current regimen ≥1 month. Three definitions nonadherence considered: missing dose, ≥2 doses, taking <95% doses past 4 weeks. Results: Over 30% reported 14.9% missed 7.1% took previous The rate drug...
Sequence data from resistance testing offer unique opportunities to characterize the structure of human immunodeficiency virus (HIV) infection epidemics.We analyzed a representative set HIV type 1 (HIV-1) subtype B pol sequences 5700 patients enrolled in Swiss Cohort Study. We pooled these with same number foreign epidemics, inferred phylogeny, and identified transmission clusters as clades having minimal size 10 containing >or=80% sequences.More than one-half were included within 60...
Between 1984 and 2006, 12 959 people with HIV/AIDS (PWHA) in the Swiss HIV Cohort Study contributed a total of 73 412 person-years (py) follow-up, 35 551 which derived from PWHA treated highly active antiretroviral therapy (HAART). Five hundred ninety-seven incident Kaposi sarcoma (KS) cases were identified whom 52 among HAART users. Cox regression was used to estimate hazard ratios (HR) corresponding 95% confidence intervals (CI). incidence fell abruptly 1996-1998 reach plateau at 1.4 per...
Objective Metabolic changes caused by antiretroviral therapy (ART) may increase the risk of coronary heart disease (CHD). We evaluated in prevalence cardiovascular factors (CVRFs) and 10‐year CHD a large cohort HIV‐infected individuals. Methods All individuals from Swiss HIV Cohort Study (SHCS) who completed at least one CVRF questionnaire for whom laboratory data were available period February 2000 to 2006 included analysis. The presence factor was determined using cut‐offs based on...
To compare the use of co-medication, potential drug–drug interactions (PDDIs) and effect on antiretroviral therapy (ART) tolerability efficacy in HIV-infected individuals according to age, ≥50 years or <50 years. All ART-treated participants were prospectively included once during a follow-up visit Swiss HIV Cohort Study. Information any current medication was obtained by participant self-report medical prescription history. The complete treatment subsequently screened for PDDIs using...